Clinical activity observed in third dosing cohort and sustained clinical benefit in second cohort AUSTIN, Texas & SOUTH SAN FRANCISCO, Calif. & HAMILTON, Ontario--(BUSINESS WIRE)--Triumvira Immunologics (“Triumvira”), a clinical-stage company develop
WINNIPEG, Manitoba--(BUSINESS WIRE)--$FDGE--Farmers Edge Inc. (“Farmers Edge” or the “Company”) (TSX: FDGE), a pure-play digital agriculture company reports its unaudited financial results for the three months ended September 30, 2022. All amounts
World’s largest independent health marketing & commercialization agency names global operations team and the first of its Managing Directors overseas TORONTO & NEW YORK--(BUSINESS WIRE)--#KlickHealth--Building on its recent news about taking the co
AUSTIN, Texas & SOUTH SAN FRANCISCO, Calif. & HAMILTON, Ontario--(BUSINESS WIRE)--Triumvira Immunologics (“Triumvira”), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology o
TORONTO--(BUSINESS WIRE)--$HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address
MADRID--(BUSINESS WIRE)-- Images: https://bit.ly/3sq16sv Fruit Attraction 2022 concluded its 14th edition with excellent results, described by the participants as very positive. Over the three days, a total of 89,535 professionals from 137 countries a
LED leader Fluence will feature products and research, lead an educational session on increasing crop performance at this year’s MJBizCon AUSTIN, Texas--(BUSINESS WIRE)--Fluence, a leading global provider of energy-efficient LED lighting solutions for
Expanded characterization of CD3-binding antibodies includes identification of antibodies that bind regions of CD3 that are distinct from commonly used molecules Robust proof-of-concept study demonstrates T-cell engagers that potently eliminate cancer
Q3 marked a meaningful quarter for partnerships with a recently announced prophylactic hepatitis B commercialization collaboration in certain European countries with Valneva, and a clinical collaboration in glioblastoma with Agenus PreHevbrio™ [Hepa
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics®, is pleased to announce that its CYB004-E Phase 1 trial evaluating N
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.